Lisinopril Price In USA
- United States: 319510 USD/MT
The price of Lisinopril in Korea for Q1 2024 reached 2,530 USD/Ton in March.
The latest report by IMARC Group, titled "Lisinopril Pricing Report 2024: Price Trend, Chart, Market Analysis, News, Demand, Historical and Forecast Data" delivers a comprehensive analysis of Lisinopril prices on a global and regional scale, highlighting the pivotal factors contributing to price changes. This detailed examination includes spot price evaluations at key ports and an analysis of pricing structures, such as Ex Works, FOB, and CIF, across North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Lisinopril Prices December 2023:
- United States: 319510 USD/MT
- Asia Pacific: 289715 USD/MT
- Europe: 338740 USD/MT
Report Offering:
- Monthly Updates: Annual Subscription
- Quarterly Updates: Annual Subscription
- Biannually Updates: Annual Subscription
The study delves into the factors affecting Lisinopril price variations, including alterations in the cost of raw materials, the balance of supply and demand, geopolitical influences, and sector-specific developments.
The report also incorporates the most recent updates from the market, equipping stakeholders with the latest information on market fluctuations, regulatory modifications, and technological progress. It serves as an exhaustive resource for stakeholders, enhancing strategic planning and forecast capabilities.
Request For a Sample Copy of the Report: https://www.imarcgroup.com/lisinopril-pricing-report/requestsample
Lisinopril Price Trend- Q4 2023
The growing prevalence of hypertension and heart-related disorders globally serves as a primary driver for the market growth of Lisinopril. This medication, a widely prescribed angiotensin-converting enzyme (ACE) inhibitor, plays a critical role in managing high blood pressure and improving survival rates after heart attacks. Additionally, the increasing incidence of diabetic nephropathy, for which lisinopril is an effective treatment, is propelling the demand for this therapeutic agent. The pharmaceutical industry's expansion, marked by significant advancements in cardiovascular disease management, also underscores the importance of lisinopril in clinical settings. The development of formulations that enhance patient compliance, such as combination pills that address multiple symptoms, is boosting the use of lisinopril. Moreover, the shift towards generic medication due to the expiration of patents on branded drugs is leading to more affordable options, thus increasing accessibility and use of lisinopril globally. The trend towards preventive healthcare measures and routine monitoring of vital signs has also increased the prescription rates of lisinopril, as it is effective in long-term management of health conditions without severe side effects. In parallel, advancements in drug delivery systems are making treatment regimens simpler and more effective, which supports market growth. Furthermore, the customization of medication dosages to cater to individual patient needs is enhancing the therapeutic efficacy of lisinopril, contributing to its widespread adoption.
Lisinopril Market Analysis
The global lisinopril market size reached US$ 226.5 Million in 2023. By 2032, IMARC Group expects the market to reach US$ 330.8 Million, at a projected CAGR of 4.30% during 2023-2032. In the last quarter of 2022, several factors influenced the pricing trends of lisinopril, a key pharmaceutical ingredient used in the treatment of hypertension and heart failure. In North America, particularly the United States, lisinopril prices saw a decline of approximately 3.6%. This decrease was primarily driven by a combination of bearish demand from the pharmaceutical and healthcare sectors and an oversupply in the domestic market. The substantial availability of lisinopril was due to excessive imports from Asia, where U.S. merchants had previously placed large orders anticipating higher demand that did not materialize. As the quarter progressed, in an effort to stimulate demand and reduce burgeoning inventories, suppliers reduced their prices. This strategic price reduction was aimed at clearing stockpiles that had accumulated due to the mismatch between supply and anticipated demand. The effect of these dynamics led to a downward price adjustment, with prices stabilizing around USD 319,500 per metric ton by the end of the quarter.
Meanwhile, the price trends in the Asia-Pacific region exhibited volatility throughout the quarter. Initially, the market opened with bearish sentiments, influenced by halted production activities during the Golden Week holiday and ongoing COVID-19 restrictions, which disrupted supply chains. However, in November, there was a temporary price increase due to a constrained supply resulting from these production halts, compounded by restricted operations amidst pandemic controls. As the restrictions began to ease in early December following China's adjustment of its zero-COVID strategy, the market did not experience the anticipated rebound in demand. This lack of recovery, coupled with muted trading activities ahead of the year-end holidays, led to a decrease in prices, culminating in a settlement of USD 289,700 per metric ton. The fluctuating demand in key markets, combined with geopolitical and economic uncertainties, played a significant role in influencing lisinopril prices across these major regions during the quarter.
Browse Full Report: https://www.imarcgroup.com/lisinopril-pricing-report
Key Points Covered in the Lisinopril Pricing Report:
The report delivers the following key findings, alongside a comprehensive breakdown of prices by region:
- Lisinopril Price Analysis
- Lisinopril Price Trend
- Lisinopril Demand & Supply
- Lisinopril Market Analysis
- Demand Supply Analysis by Type
- Demand Supply Analysis by Application
- Demand Supply Analysis of Raw Materials
- Lisinopril Price Analysis
- Lisinopril Industry Drivers, Restraints, and Opportunities
- Lisinopril News and Recent developments
- Global Event Analysis
- List of Key Players
Regional Price Analysis:
- Asia Pacific: China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand.
- Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal and Greece.
- North America: United States and Canada.
- Latin America: Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru
- Middle East & Africa: Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco.
Browse More Pricing Reports By IMARC Group:
Note: The current country list is selective, detailed insights into additional countries can be obtained for clients upon request.
About Us:
IMARC is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
